General
Preferred name
PIRTOBRUTINIB
Synonyms
LOXO-305 ()
LY-3527727 ()
LY3527727 ()
RXC-005 ()
Pirtobrutinib (LOXO-305) ()
LY 3527727, RXC-005 ()
Jaypirca ()
P&D ID
PD154967
CAS
2101700-15-4
Tags
available
drug
Approved by
FDA
First approval
2023
Drug indication
Small lymphocytic lymphoma
Chronic lymphocytic leukaemia
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Pirtobrutinib (LOXO-305, MCL-133) is a selective and reversible (non-covalent), oral Bruton's tyrosine kinase (BTK) inhibitor that was originally developed by LOXO oncology (now Lilly Oncology) for potential to treat B cell malignancies . It binds within the BTK kinase pocket but its interaction does not rely on the C481 residue that is essential for the activity of earlier irreversible BTK inhibitors (, , and ). Therefore, it is expected to be active in cancers with wild type BTK or with C481 resistance mutations. (GtoPdb)
DESCRIPTION On January 2023, FDA approved Pirtobrutinib to treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitor (PKIDB)
DESCRIPTION Pirtobrutinib is a Bruton's tyrosine kinase (BTK) inhibitor and antineoplastic agent. (BOC Sciences Bioactive Compounds)
Compound Sets
13
BOC Sciences Bioactive Compounds
pirtobrutinib-cas-2101700-15-4-372922
Cayman Chemical Bioactives
36775
ChEMBL Approved Drugs
CHEMBL4650485
ChEMBL Drugs
CHEMBL4650485
DrugBank
DB17472
DrugBank Approved Drugs
DB17472
DrugCentral
5709
DrugCentral Approved Drugs
5709
DrugMAP
DMRG1X3
Guide to Pharmacology
11628
MedChem Express Bioactive Compound Library
HY-131328
PKIDB
Selleckchem Bioactive Compound Library
pirtobrutinib-loxo-305
External IDs
15
Properties
(calculated by RDKit )
Molecular Weight
479.16
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
3
Rotatable Bonds
7
Ring Count
3
Aromatic Ring Count
3
cLogP
3.43
TPSA
125.26
Fraction CSP3
0.23
Chiral centers
1.0
Largest ring
6.0
QED
0.45
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Protein Tyrosine Kinase/RTK
Target
BTK
Solubility
Soluble in DMSO
Source data